Adverse events: hypertension · patients with the anaemia of end‐stage kidney disease undergoing dialysis
CERA showed no clear difference in numbers of adverse events due to hypertension: CERA every 2 weeks… compared with other ESA (high certainty).
1 finding from 1 review
Numbers of adverse events due to access thrombosis · patients with the anaemia of end‐stage kidney disease undergoing dialysis
CERA showed no clear difference in numbers of adverse events due to access thrombosis: CERA every 2… compared with other ESA (moderate certainty).
1 finding from 1 review
Adverse events · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events:incarceration Assessed by: incarceration between a 3‐ and 9‐month · adults with antisocial personality disorder
It is very uncertain whether impulsive lifestyle counselling + treatment‐as‐usual changes adverse events:incarceration Assessed by: incarceration between a 3‐… compared with treatment‐as‐usual alone (very low certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with active UC
Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · patients with induction of remission in ulcerative colitis
Etrolizumab probably leads to lower adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Any adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · people in remission or with mildly activeulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review